Join us for this unique opportunity to learn about how new advances in nuclear medicine and molecular imaging are being used to diagnose and treat disease.

@update_in_nm Used Re-188 first in 1988!!

@Michael_LeeChin Michael, how can I become involved with the Family Office Forum? I noticed there is a meeting here in Wiesbaden in SEP Best, Richard

@GUOncologyNow @myESMO q.e.d. See our JNM PAPER 2016

@CalaisJeremie @kuppermann @wayne_brisbane @UclaUrology @JUrology Indeed, very important to integrate molecular imaging in the regular workout of related specialties- congratulations for this masterpiece!

@CalaisJeremie @Prof_Ezziddin My answer referred to Chris, and not to your comment. Tc is not useful for very early stage disease…

@Globeseek @NANETS1 Hi Bill, good to hear from you after such a long time! Would you be interested to come to Germany for the 6th Theranostics World Congress end of June?

@OncoThor Very saddened to hear that Tom passed away. He was such a great person and friend. He was the first in US to recognize the potential of PRRT. I still remember his lecture at the 1st Theranostics World Congress in 2011 and meeting him/Sue end of 2019 at my Farewell in Bad Berka.

@jonbonjovi And objects in the rear view mirror may appear closer than they are

@jonbonjovi And if life is just a highway, then the soul is just a car

I am speaking at International Conference on Radiopharmaceutical Therapy. Please check out my talk if you're attending the event! #icrt16 - via #Whova event app

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, pha...

@NargesJokar @ClinNuclearMed I am sorry, but LuFAPI will not work. AUC=radiation dose to tumor is too small due to low uptake, but mainly to short residence time in tumor. See our paper in J Nucl Med on using FAP PEPTIDE which gives better, but still not enough radiation dose to CAFs.TANDEM =Solution!

@AliSalavatiMD @NEJM Agree, another milestone paper after the NETTER-1 trial published in the NEJM in 2017. However, the reference list gives zero credit to the first LuPSMA treatment ever by my team in 2013 (published in the JNM in 2016). Clinal development in Germany was important for breakthrough

@Globeseek @marklewismd @tmprowell @helops79 @JaydiDelRivero I’m very happy to see that my prediction became true! All the best for you Josh and your wonderful son for the next years to come!

@Mechacortarl Ja, das ist möglich. Zuvor muss jedoch ein PSMA PETCT erfolgen. Kontaktdaten unter

@DrMHofman @thomashopemd @ANZUPtrials We will need more of these excellent trials in RPO (RadionmolecularPrecisionOncology) - well designed and supported by the oncologists - exactly that is what is the hallmark of your outstanding efforts. When you will present the OS data?